Insilico Medicine, Lilly Partner on AI-Driven Drug Discovery Deal
Insilico Medicine and Eli Lilly have entered a partnership to use Insilico’s AI‑driven Pharma.AI platform for discovering new oral therapeutics across several disease areas. Lilly receives an exclusive worldwide license to develop, manufacture and commercialize the preclinical candidates, while Insilico secures a $115 million upfront payment and potential milestones up to $2.75 billion. The collaboration blends Insilico’s computational expertise with Lilly’s development capabilities, establishing joint R&D programs focused on Lilly‑selected targets. Tiered royalties will apply to future sales, aligning long‑term incentives for both parties.
New Data Show TrenibotE Safety in Repeat Treatments
Allergan Aesthetics presented new Phase 3 data on its investigational neurotoxin TrenibotE at the 2026 American Academy of Dermatology meeting. The open‑label study evaluated up to three repeat glabellar line treatments, confirming a consistent safety profile, no neutralizing antibodies, rapid onset...
Elidah Reports US FDA Clearance of Elitone for Men to Treat Post-Prostatectomy Urinary Incontinence
Elidah announced that the U.S. Food and Drug Administration has cleared its at‑home device, Elitone for Men, to treat urinary incontinence after prostate surgery. The non‑invasive system delivers neuromuscular stimulation to the pelvic floor for a 20‑minute daily session, eliminating...
3 Career Moves R&D Professionals Must Make in a Skills-Based, AI-Driven Economy
Biopharma R&D careers are shifting from title‑driven ladders to skills‑centric portfolios as AI automates routine tasks. Professionals must treat each role as an opportunity to acquire execution‑level capabilities, use generative AI to deepen scientific judgment, and continuously assess and market...
The Brave New World of Radiotherapeutics
Radiotherapeutics have moved from niche concepts to a burgeoning oncology platform, driven by unmet treatment gaps and the commercial breakthrough of Novartis' Pluvicto. Early data show Actinium‑225 delivering 45‑50% response rates in heavily pre‑treated prostate cancer, while Bayer's Xofigo adds...
AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure
AskBio, a Bayer subsidiary, announced that enrollment for its GenePHIT Phase 2 trial of the investigational gene therapy AB‑1002 has been completed, randomizing 173 patients with non‑ischemic cardiomyopathy and NYHA Class III heart‑failure symptoms. The trial, spanning 46 sites across North America...
The Deep-Tech Founder Using AI to Address Immunology Challenges
Camille Bouget, CEO and co‑founder of Scienta Lab, launched EVA, a multimodal AI platform designed to accelerate immunology drug development. The model helps R&D teams identify viable therapeutic targets, predict preclinical efficacy, and stratify patients for clinical trials. By applying...
How GLP-1 Is Impacting Food and Beverage Consumption in Australia
GLP-1 receptor agonists, originally developed for type‑2 diabetes, are rapidly being prescribed for weight management in Australia, with about 500,000 users today and projections that 10% of the population could be on the drugs by 2030. Their appetite‑suppressing effect is...
Regulating Payment of Participant Data in Clinical Trials
A team of scholars led by Steve Calandrillo proposes that FDA and IRBs adopt fair‑market‑value (FMV) payments for the data participants generate in clinical trials. Currently, participants receive modest compensation—about $4,000 per year—solely for trial involvement, not for the valuable...
The Role of Ethical Oversight and Algorithmic Bias in Automated Pharmacovigilance
Pharmacovigilance is rapidly adopting machine learning, natural language processing, and automation to ingest, categorize, and prioritize adverse event reports, dramatically shrinking backlogs and accelerating signal detection. While these technologies deliver speed and scale, they also inherit reporting biases and can...
Wegovy to Reach 1.2 Million Additional NHS Patients
Novo Nordisk $NVO obesity drug Wegovy will be an option for about 1.2 million more patients in England’s National Health Service - Bloomberg
Biotech Edge: XBI Up 0.9% Amid Market Slump
With today's notable strength in biotech, I note that the XBI was actually marginally positive for the month (0.9%) - seems to be the only sector outside energy that was positive for the month. There have been a modest but...
Lantern Pharma Narrows Q4 Loss, Schedules FDA Type C Meeting for LP‑300 in May 2026
Lantern Pharma Inc. posted a narrower fourth‑quarter net loss and saw its stock rise 26.3% to $1.56. The company also confirmed a mid‑May 2026 FDA Type C meeting for LP‑300, its phase‑2 lung‑cancer therapy, underscoring a pivotal regulatory milestone for...
Study's COVID Vaccine Benefits Limited to Early Pandemic
This tweet and accompanying paper are fairly misleading (note: paper is from July ‘24) There are many issues w the study itself that it’s a bit tough to go into here. But most importantly, the paper concludes: “Our findings support the...
Terminal Plasmid Editor Blends Beauty with Functionality
Vibing some more on my in-terminal plasmid editor. Drafting a parts bin that's aesthetically pleasing but also functional. TUI's are wonderful. https://t.co/yu8WUSLgwA
Scholar Rock’s Apitegromab BLA Resubmission Boosts Stock 11% in Pre‑Market
Scholar Rock Holding Corp. resubmitted its Biologics License Application for apitegromab to the FDA, adding a second U.S. fill‑finish site to secure supply. The move lifted the shares about 11% in early trading and positions the company for a PDUFA...
Adiponectin: Key Protector Against Age‑Related Decline
Adiponectin and aging: Mechanistic insights, clinical paradox, and therapeutic horizons "Adiponectin has been implicated in aging and the onset of age-related disease.... Adiponectin signaling protects multiple tissues from age-associated decline... Adiponectin signaling agonists as therapeutics in metabolic and age-related disease." https://t.co/9NcjtjlbjR
Implantable Islet Cells Offer Injection-Free Diabetes Control
Implantable islet cells could control diabetes without insulin injections by Anne Trafton @MIT Learn more: https://t.co/aPCxukXMW1 #MedTech #HealthTech #Tech #TechForGood https://t.co/hXbxvs5HTM
Eli Lilly to Acquire Centessa in $7.8 B Deal, Stock Jumps 45%
Eli Lilly agreed to buy Centessa Pharmaceuticals for up to $7.8 billion, paying $38 per share in cash plus a contingent value right worth up to $9 per share. The announcement lifted Centessa’s Nasdaq price 45% to a 52‑week high, underscoring...
NineDiagnostics Joins SCbio‑MassBio Drive for AI Cancer Detection
Proud to announce that @NineDiagnostics has been selected for Spring 2026 @SCbio × @MassBio Drive — #biomarkers & #diagnostics track 🎉 One of 11 selected companies. We're focused on building AI-enabled tools to redefine earlier cancer detection and treatment decisions....
Gerontologist Aubrey De Grey Says Medicine Could Outpace Aging Within Two Decades
Aubrey de Grey, founder and CSO of the Longevity Escape Velocity Foundation, told listeners of Longevity Technology Unlocked that emerging therapies could rejuvenate people in their 60s back to a biological age of 40, buying roughly 20 years for further...
Agios Pursues Accelerated FDA Approval for Mitapivat as Sickle‑Cell Therapy, Shares Jump 21%
Agios Pharmaceuticals announced it will seek accelerated U.S. approval for its oral drug mitapivat to treat sickle‑cell disease, prompting a 21.7% rise in its shares. The company has already filed a confirmatory trial proposal with the FDA and is preparing...
Spermidine Linked to Heritable Red Blood Cell Longevity Trait
The longevity factor spermidine is part of a highly heritable complex erythrocyte phenotype associated with longevity https://t.co/rHT8XoWHFz
Antipsychotic-Like Effects of the Selective Rho-Kinase 2 Inhibitor KD025 in Genetic and Pharmacological Mouse Models of Schizophrenia
The selective ROCK2 inhibitor KD025 (belumosudil) demonstrated antipsychotic‑like activity in both genetic (Arhgap10 S490P/NHEJ) and pharmacological (methamphetamine and MK‑801) mouse models of schizophrenia. KD025 restored reduced spine density in the medial prefrontal cortex and rescued deficits in a touchscreen visual‑discrimination...
Jupiter Neurosciences Inc (JUNS) Q4 2025 Earnings Call Transcript
Jupiter Neurosciences reported total product sales of $2.8 billion in 2025, a 22% year‑over‑year increase driven by INGREZZA and the debut of CRENESSITY. INGREZZA generated just over $2.5 billion, up 9% on volume growth, while CRENESSITY posted $300 million in its first full...
Cysteine Steers T‑cells Toward Proliferation or Tumor Killing
Cysteine directs T cells to either multiply or attack tumors by fueling distinct metabolic pathways, suggesting new strategies to fine-tune immune responses in cancer therapy. immunometabolism
From Free Rider to Innovator: How China Became a Global Pharmaceutical Powerhouse
China has transformed from a pharmaceutical free rider into a leading innovator, largely after the 2016 National Reimbursement Drug List (NRDL) reform. The policy slashed prices by 50‑60% while guaranteeing near‑universal coverage, prompting a five‑fold rise in annual clinical trials...
Reactivation of Dormant Regulatory T Cells Alleviates Asthma Symptoms in Mice
Researchers at Henan Academy, Zhengzhou University and Shenzhen University demonstrated that activating the Dectin‑1 receptor on regulatory T cells (Tregs) can reverse their dormant, senescent state and restore anti‑inflammatory function. Using the small peptide KQS‑1, they epigenetically up‑regulated FOXP3 and...
Genetic Variants Involved in Rapid Immune Response Linked to Earlier Breast Cancer Onset in BRCA1 Carriers
Researchers identified damaging variants in innate immunity genes, especially those governing natural killer (NK) cell activation, as strong modifiers of breast cancer onset in women carrying the BRCA1 185delAG mutation. An analysis of 321 Ashkenazi Jewish carriers showed that these...
28 Months Later: FDA Still Hasn't Revealed Rick Bright and Janet Woodcock's Communications
The episode delves into the controversy surrounding the FDA’s handling of hydroxychloroquine during the COVID‑19 pandemic, focusing on whistleblower Dr. Rick Bright’s claims that Dr. Janet Woodcock pressured him to pursue an Emergency Use Authorization (EUA) rather than an expanded‑access protocol....
Shields and Bodyguards: Scientists Uncover the Hidden Defenses of a Deadly Childhood Cancer
University of Queensland researchers applied spatial multi‑omics to 27 neuroblastoma samples, creating high‑resolution maps that reveal a GPX4‑driven shield protecting tumor cells from ferroptosis and surrounding immune cells acting as "bodyguards." The study, published in Genome Medicine, identifies GPX4 as...
The War on Peptides — Why Retatrutide Is at the Center
In this episode of Business Game Changers, host Sarah Westall and Dr. Diane Kayser discuss the rapidly evolving peptide market, focusing on the upcoming weight‑loss peptide retatrutide (also called Reditrutide). They explain how big‑pharma is moving to control peptide supplements,...
TYK2 Protein Suppresses Breast Cancer Metastasis by Sensing Extracellular Stiffness, Research Finds
Researchers at UC San Diego discovered that the inflammatory protein TYK2 acts as a metastasis suppressor in breast cancer by sensing extracellular matrix stiffness. On soft matrices, TYK2 remains on the cell membrane and blocks invasion, while stiff environments cause...
Dual-Target Strategy Shows Promise in Overcoming Drug Resistance in MCL
A recent preclinical study identified BIRC5 and MCL‑1 as co‑drivers of survival in mantle cell lymphoma (MCL) and demonstrated that simultaneous inhibition with YM155 and S63845 produces strong synergistic killing of cancer cells. The combination was effective across both treatment‑naïve...
Targeting Tumor Supporting Cells: Lipid Nanoparticles Advance CAR T Success in Pancreatic Cancer
Researchers at Penn Vet used lipid nanoparticles (LNPs) to deliver FAP‑CAR mRNA directly to patients' T cells, enabling in‑vivo engineering of CAR T cells that attack cancer‑associated fibroblasts in pancreatic ductal adenocarcinoma. In a preclinical mouse model, a single dose of...
BREAKING STUDY: Half of COVID-19 Vaccinated Military Personnel Suffered Subclinical Heart Stress
A new longitudinal study of 83 healthy military personnel tracked cardiac biomarkers after two mRNA COVID‑19 vaccine doses. Within two weeks of the second shot, 49% of participants exhibited a rise in NT‑proBNP exceeding 1.5 times their baseline, indicating subclinical...
A Startup Has Been Quietly Pitching Cloned Human Bodies to Transfer Your Brain Into
Stealth biotech startup R3 Bio, backed by billionaire investors, announced a fundraising round to develop non‑sentient monkey organ‑sack platforms for donor organs. Investigative reporting by MIT Technology Review revealed that the founders are also exploring the far more controversial concept...
Off-the-Shelf CAR T-Cell Therapy Granted Breakthrough Therapy Designation for Aggressive T-Cell Cancers
Soficabtagene geleucel (WU‑CART‑007), an off‑the‑shelf CRISPR‑engineered CAR‑T therapy, received FDA Breakthrough Therapy Designation for relapsed or refractory T‑cell leukemia and lymphoma. In a phase 1/2 trial of 28 patients, the drug achieved a 91% overall response rate and a 73% complete...
Lipidomics Study Maps Diet to Heart‑Health Risk, Paving Way for Precision Nutrition
Researchers led by Beyene, Wang and Cinel published a landmark lipidomics analysis in Nature Communications that ties distinct lipid profiles to dietary patterns and cardio‑metabolic outcomes, offering a molecular roadmap for precision nutrition.
Using “Left-Handed” Proteins to Block Alzheimer’s
Kobe University researchers engineered a synthetic right‑handed (D) peptide that binds amyloid‑beta, the disordered protein driving Alzheimer’s plaques, and blocks its aggregation. In mouse brain cell cultures the mirror peptide restored cell viability to 100%, compared with 50% survival when...
First‑In‑Human Nuclease‑Free Gene Editing Shows Promise for Methylmalonic Acidemia
Researchers led by Dr. Bedoyan, Dr. Morgan and Dr. Sun completed a phase 1/2 trial that used nuclease‑free homologous recombination to edit the genes of children with methylmalonic acidemia. The therapy lowered toxic metabolite levels and showed durable engraftment without...
FDA Set to Lift Peptide Compounding Ban After RFK Jr. Push
The Food and Drug Administration is preparing to reverse its 2023 restriction on dozens of experimental peptides, permitting licensed compounding pharmacies to produce them again. The move follows Health Secretary Robert F. Kennedy Jr.’s public promise on the Joe Rogan...
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Nanobiotix posted full‑year 2025 results showing a revenue rebound to roughly $35.5 million and a net loss of $26 million, a 65% YoY improvement. The company secured a non‑dilutive royalty financing of up to $71 million, extending its cash runway to early 2028 with...
Low Placebo Response Skews Psychedelic Depression Trial Results
I was interviewed about a study of GH001, vaporized 5-MeO-DMT, for treatment-resistant depression. I commented that, while promising and encouraging, the thing that popped out to me was the almost complete lack of placebo response in the placebo group. Even...
Biogen to Acquire Apellis for $5.6 B, Shares Jump 136% on Deal
Biogen announced a definitive agreement to buy Apellis Pharmaceuticals for $41 a share in cash, valuing the transaction at roughly $5.6 billion. The deal lifts Apellis shares 135.7% to $40.28 and adds two marketed complement‑inhibitor drugs, EMPAVELI and SYFOVRE, to Biogen’s...
Frailty, Innovation, and the Future of Myeloma Treatment With Joseph Mikhael, MD
Joseph Mikhael, MD, highlights a dramatic shift in multiple myeloma care for older adults, driven by refined frailty assessments and the rise of targeted immunotherapies such as CAR‑T cells and bispecific antibodies. These advances have translated into higher survival rates...
New Sensor Could Allow MRIs to See Molecular-Level Changes
University of California, Santa Barbara researchers have engineered a genetically encoded, protein‑based sensor that lets magnetic resonance imaging capture molecular‑level activity inside cells. The modular system, called MAPPER, couples aquaporin water channels with interchangeable protein domains to generate MRI‑detectable signals...
Key Neurons Can Jumpstart Leg Movement After Spinal Injury
Researchers identified a rare subset of graft‑derived interneurons that can reconnect broken spinal circuits and trigger leg muscle activity in animal models of spinal cord injury. When these neurons were experimentally activated, 20‑30% of the subjects showed measurable leg movements,...
Elaine Chen Showcases Biotech Deals and Mind‑bending Insights
I'd like to draw your attention to my fantastic @statnews colleague @elaineywchen. She led the way our obesity drug coverage, is a host on our podcast, and writes our biotech newsletter most days. Today has two big examples of the...
Killer Cells Eradicate Superbugs in a Single Day
Forget Antibiotics: These Killer Cells Wipe Out Deadly Superbugs in a Day by @ShellyFan https://t.co/KVAaK61555 https://t.co/cXP8loNRHn